Montreal based Optina Diagnostics Inc., a leader in early detection of Alzheimer through the use of Artificial Intelligence (AI) and Spectral Retinal Imaging, has raised C$4 million in a new round of funding to scale up its clinical development and accelerate its growth and market readiness.
The round was led by Zoic Capital with other key strategic partners, Desjardins Capital, DigitalDx Ventures, Pallasite Ventures, Barney Pell, Barney Pell's AngelList Syndicate, Advisors fund and Hike Ventures also participating in the round.
Due to the strong clinical data gathered through the financial support of CQDM- Biopharmaceutical Research Consortium and CTS at Montreal, Optina is ready to extend its clinical sites and focus on the regulatory approval of it's cerebral Amyloid prediction test.
